Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Biotronik, Inc.
ClinicalTrials.gov Identifier:
NCT00836589
First received: February 2, 2009
Last updated: May 13, 2014
Last verified: May 2014
  Purpose

The objective of this study is to confirm the long-term safety and reliability of the Linox Lead System as used with BIOTRONIK ICDs. The GALAXY registry will provide data to fully characterize ICD lead failures, from implant through 5 years, including those failures contributing to patients losing pacing or defibrillation therapy.


Condition Intervention
Patients Indicated for an ICD
Device: ICD Therapy - ICD Lead Registry

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: GALAXY Registry: Long-term Evaluation of the Linox Family ICD Leads Registry

Further study details as provided by Biotronik, Inc.:

Primary Outcome Measures:
  • Overall complication-free rate [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 2000
Study Start Date: December 2008
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Data Collection Group Device: ICD Therapy - ICD Lead Registry
Collecting long-term safety and efficacy data on a family of market-released ICD leads.

Detailed Description:

This study is a multi-center, prospective, non-randomized, 5-year data collection registry. Eligible patients must have been successfully implanted with a Linox Lead System connected to a BIOTRONIK ICD and consented and enrolled between 1-45 days following implant. This study is designed to be a post-implant (office-based) registry, and patients are meant to be seen according to each institution's standard of care, but not to exceed a follow-up time frame of every 6 months. At least 2000 patients will be enrolled in this registry, and each patient will be followed for five years post-implant.

Safety will be evaluated based on the analysis of the overall incidence of lead-related adverse events that require additional invasive intervention to resolve. In addition, each individual adverse event will be separately investigated. Lead parameters for sensing, pacing thresholds, and impedance will also be evaluated. An independent Clinical Events Committee will review and adjudicate all adverse events that occur during the study according to the protocol definitions.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients will be obtained from the investigators' general patient population according to the inclusion and exclusion criteria described below.

Criteria

Inclusion Criteria:

  • Successfully implanted Linox Lead System connected to a BIOTRONIK ICD, from 1-45 days prior to enrollment
  • Able to understand the nature of the registry and provide informed consent
  • Available for follow-up visits on a regular basis at the investigational site
  • Age greater than or equal to 18 years

Exclusion Criteria:

  • Enrolled in any IDE clinical study
  • Planned cardiac surgical procedures or investigational measures within the next 6 months
  • Expected to receive a heart transplant within 1 year
  • Life expectancy less than 1 year
  • Presence of another life-threatening, underlying illness separate from their cardiac disorder
  • Pregnancy
  • Inability to provide date of implant, devices implanted, age, gender, and whether the patient experienced any protocol-defined adverse events since implant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00836589

  Hide Study Locations
Locations
United States, Alabama
Albertville, Alabama, United States
Birmingham, Alabama, United States
Gadsden, Alabama, United States
Jasper, Alabama, United States
United States, Arizona
Glendale, Arizona, United States
Mesa, Arizona, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
United States, California
Burbank, California, United States
Fairfield, California, United States
Fountain Valley, California, United States
Glendale, California, United States
Hawthorne, California, United States
Inglewood, California, United States
Los Angeles, California, United States
Mission Viejo, California, United States
Northridge, California, United States
Rancho Mirage, California, United States
Santa Barbara, California, United States
Santa Maria, California, United States
Torrance, California, United States
United States, Colorado
Aurora, Colorado, United States
Boulder, Colorado, United States
United States, Florida
Brooksville, Florida, United States
Daytona Beach, Florida, United States
Inverness, Florida, United States
Jacksonville, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
New Smyrna Beach, Florida, United States
Pensacola, Florida, United States
Port Charlotte, Florida, United States
Sebastian, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Alton, Illinois, United States
Centralia, Illinois, United States
Chicago, Illinois, United States
United States, Indiana
Hammond, Indiana, United States
Jeffersonville, Indiana, United States
United States, Kentucky
Owensboro, Kentucky, United States
United States, Louisiana
Lafayette, Louisiana, United States
Lake Charles, Louisiana, United States
Marrero, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
Cumberland, Maryland, United States
Rockville, Maryland, United States
Salisbury, Maryland, United States
United States, Michigan
Grand Rapids, Michigan, United States
Ypsilanti, Michigan, United States
United States, Mississippi
Biloxi, Mississippi, United States
United States, Missouri
Bridgeton, Missouri, United States
Crystal City, Missouri, United States
St. Louis, Missouri, United States
United States, New Jersey
Haddon Heights, New Jersey, United States
United States, New York
Rochester, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
Concord, North Carolina, United States
Gastonia, North Carolina, United States
Greensboro, North Carolina, United States
United States, North Dakota
Grand Forks, North Dakota, United States
United States, Ohio
Columbus, Ohio, United States
Massillion, Ohio, United States
Toledo, Ohio, United States
Zanesville, Ohio, United States
United States, Oregon
Portland, Oregon, United States
Salem, Oregon, United States
United States, Pennsylvania
Chinchilla, Pennsylvania, United States
Phoenixville, Pennsylvania, United States
Yardley, Pennsylvania, United States
United States, South Carolina
Columbia, South Carolina, United States
Florence, South Carolina, United States
Greenville, South Carolina, United States
Greenwood, South Carolina, United States
Lancaster, South Carolina, United States
Rock Hill, South Carolina, United States
United States, Tennessee
Chattanooga, Tennessee, United States
United States, Texas
Amarillo, Texas, United States
El Paso, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
Kingwood, Texas, United States
McAllen, Texas, United States
McKinney, Texas, United States
United States, Washington
Yakima, Washington, United States
Sponsors and Collaborators
Biotronik, Inc.
  More Information

No publications provided

Responsible Party: Biotronik, Inc.
ClinicalTrials.gov Identifier: NCT00836589     History of Changes
Other Study ID Numbers: GALAXY
Study First Received: February 2, 2009
Last Updated: May 13, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Biotronik, Inc.:
Long-term safety and reliability of ICD leads

ClinicalTrials.gov processed this record on November 20, 2014